

IntelliSyn spun out following the closure of AstraZeneca's Montreal Research site. 85% of our staff have Ph.Ds and 10-15 years' experience. We work with our partners to co-invest in project advancement. Since our inception in 2012, our scientists have filed 16 patent applications, we have been awarded with 3 governmental grants, and we have identified 2 clinical candidates. Our focus is on pre-clinical R&D in cancer and CNS drugs.

We are hiring synthetic and medicinal chemists with Ph.D. or highly experienced M.Sc. degree. Ideal candidates will be very experienced in synthesis with special emphasis in areas including heterocyclic chemistry, functional group interconversions, stereoselective methodologies, aryl/aryl couplings and related areas. The primary remit of this position is to efficiently design and execute multi-step syntheses where little or no precedence exists.

Our people have thorough knowledge of both classical and cutting-edge synthetic methodologies. Our environment fosters, encourages, and expects continued growth and contribution toward medicinal chemistry understanding and design.